CorMedix Inc. (NASDAQ:CRMD) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Dan Ferry – Managing Director-LifeSci Advisors Khoso Baluch – Chief Executive Officer Phoebe Mounts – Executive Vice President and General Counsel Matt David – Executive Vice President and Chief Financial Officer Conference Call Participants Andrew D'Silva – B. Riley FBR Ram Selvaraju – H.C. Wainwright Operator Greetings, and welcome to the CorMedix, Inc. Second Quarter 2020 Earnings Call. At this ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-34673 CORMEDIX INC. (Exact Name of Registrant as Specified in Its Charter) | --- | --- | |------------------------ ...

CorMedix, Inc. (NASDAQ:CRMD) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors Khoso Baluch - CEO & Director Matt David - EVP & CFO Phoebe Mounts - EVP, General Counsel, Secretary & Head, Regulatory, Compliance and Legal Paul Chew - Acting Chief Medical Officer Conference Call Participants Andrew D'Silva - B. Riley FBR Operator Good day, everyone, and welcome to the CorMedix Inc. First Quarter 2020 Earnings Conference Call. Today's call is being re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-34673 CORMEDIX INC. (Exact Name of Registrant as Specified in Its Charter) | --- | --- | |----------------------- ...

CorMedix, Inc. (NASDAQ:CRMD) Q4 2019 Earnings Conference Call March 16, 2020 4:30 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Khoso Baluch - Chief Executive Officer Phoebe Mounts - Executive Vice President and General Counsel Conference Call Participants Andrew D'Silva - Riley & Company Ram Selvaraju - H.C. Wainwright Operator Greetings. Welcome to the CorMedix Inc. Fourth Quarter and Fiscal Year 2019 Earnings Call. [Operator Instructions] Please note this conference is being recorded. I'll ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Delaware 20-5894890 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 Par Value CRMD NYSE American LLC FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR ...

CorMedix, Inc. (NASDAQ:CRMD) Q3 2019 Earnings Conference Call November 14, 2019 4:30 PM ET CompanyParticipants Dan Ferry - MD, LifeSci Advisors Khoso Baluch - CEO Phoebe Mounts - EVP & General Counsel Jack Armstrong - EVP, Technical Operations Bob Cook - CFO Conference Call Participants John Ledon - Novel Consulting Group Operator Greetings. Welcome to CorMedix's Inc. Third Quarter 2019 Earnings Conference Call. [Operator Instructions] Please note, this conference is being recorded. I would now like to turn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 20-5894890 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value CRMD NYSE American LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSU ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | HarnessingTaurolidine | | | | | | | | | | Technology Leading Development of Novel Anti-Infective Products in the Era of Increasing Bacterial Resistance Cantor Global Healthc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-34673 CORMEDIX INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894890 (State or Other Jur ...